Navigation Links
Nektar Presents Positive Proof-of-Concept Clinical Data for Its New Opioid Molecule, NKTR-181, at American Academy of Pain Medicine's 28th Annual Meeting
Date:2/27/2012

a wide range of doses, over multiple days of dosing, and also achieves a sustained analgesic response.  By slowing the rate of entry into the brain, NKTR-181 is designed to have less euphoria, sedation and respiratory depression than traditional opioid compounds. Individuals with a higher risk of abusing opioids prefer rapid onset of euphoria, which means NKTR-181 should be less attractive as a drug of abuse.  NKTR-181 represents an exciting developmental advance in pain.  This new human data support its further clinical development as a compelling therapeutic for the treatment of chronic pain."

Data presented at AAPM show the positive analgesic properties of NKTR-181 in humans. NKTR-181 produced dose-dependent analgesic responses in two separate models of pain used to measure central and peripheral analgesic activity in healthy subjects.  In a cold-pressor test pain model measuring latency-to-hand-removal (LHR), the 200 mg dose of NKTR-181 given twice-daily over the 8-day dosing period demonstrated the extent and duration of analgesic effect of NKTR-181 administration.  Results show a significant analgesic effect as compared to placebo (P<0.01, n=12) over the entire dosing period.  In addition, a model of induced UVB injury was also used to demonstrate the extent and duration of analgesic effect produced by NKTR-181.  Results show that NKTR-181 has both centrally-mediated and peripherally-mediated analgesic effects.  In this model, data was presented on NKTR-181 at doses of 300 mg and 400 mg demonstrating its significant analgesic and anti-hyperalgesic effect (measured as change from baseline) following mechanical and thermal stimulation, with p-values of P<0.009 and P<0.03, respectively (n=12). 

"The data from this study reinforce our belief that NKTR-181 could potentially transform the treatment of chronic pain," said Robert Medve, MD, Chief Medical Officer at Nektar Therapeutics.  "Unique
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2011 on Wednesday, February 29, 2012, After Close of U.S.-Based Financial Markets
2. Positive Data for Nektars New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011
3. Nektar Therapeutics Reports Third Quarter 2011 Financial Results
4. Nektar to Announce Financial Results for the Third Quarter of 2011 on Wednesday, November 2, 2011, After Close of U.S.-Based Financial Markets
5. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the UBS 2011 Global Life Sciences Conference in New York City
6. Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain
7. Nektar Therapeutics Reports Second Quarter 2011 Financial Results
8. Nektar to Announce Financial Results for the Second Quarter of 2011 on Thursday, August 4, 2011, After Close of U.S.-Based Financial Markets
9. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2011 Global Healthcare Conference in New York
10. Nektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting
11. FDA Grants Orphan Drug Designation for Nektars Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)...  Finesse expands office in Leicester, United ... expansion of its operations in Leicester ... access for customers is expected shortly afterward. ... to the current office, the new premises will double ... allow Finesse to bring on more service personnel. The ...
(Date:2/26/2015)... CHICAGO, Ill. , Feb. 26, 2015 /PRNewswire/ ... that 15 abstracts of studies in its neuroscience ... presentation during the 67 th American Academy ... D.C. , from April 18-25. The accepted ... product, DUOPA, in addition to investigational treatments in ...
(Date:2/26/2015)... Feb. 26, 2015  Mobility Ventures LLC, an AM ... Bank of America (NYSE: BAC ) that ... financing of the revolutionary MV-1 - - the world,s ... ground up to provide safe and comfortable transportation for ... their loan to purchase a new MV-1 vehicle at ...
Breaking Medicine Technology:New Finesse Office in United Kingdom 2AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 2AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 3AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 4AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 5AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 6AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 7Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 2Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 3
(Date:2/28/2015)... The noted Friedman Dental Group of South ... relaunched their website. The new version of the site ... new section about their team members. Potential and current ... of each Friedman Dental Group team member including new ... to provide our patients with the opportunity to get ...
(Date:2/28/2015)... 2015 Developers of FCPX plugins ... overlay plugin for Final Cut Pro X entitled FCPX Overlay ... Chromatic gives users total control over 6k lens dirt overlays ... Pixel Film Studios. “FCPX Overlay Chromatic was professionally designed to ... interface.” , FCPX Overlay Chromatic Grunge 6K is a resourceful ...
(Date:2/28/2015)... “ Powermod ” was featured on NewsWatch as ... at the latest and coolest technology products and services available ... a technology expert, conducted the review and shared with viewers ... Getting stuck with a low battery and no way to ... face on a daily basis. Even when a person does ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 Memphis, TN: ... 5, 2015, for a new security reader named ... The reader is a new biometric scanner that ... with new features, the new biometric scanner provides ... and administrators. , MedixSafe narcotics lockers ...
(Date:2/28/2015)... Las Vegas, NV (PRWEB) February 28, 2015 ... products, will be sending a team to Las Vegas, Nevada ... ASD Market Week is one of the leading consumer-goods tradeshows ... 2,600 vendors at this year’s event. My Shiney Hiney can ... delivers a fresh, modern design for the at-home personal hygiene ...
Breaking Medicine News(10 mins):Health News:Friedman Dental Group Announces Their Updated Website 2Health News:Pixel Film Studios released a new overlay plugin entitled FCPX Overlay Chromatic Grunge 6K exclusively for Final Cut Pro X users 2Health News:Solutions to Keep Phones Charged were Featured on NewsWatch Television on January 29, 2015 2Health News:New Name Announced For Newest MedixSafe Readers – MedixSafe Vanguard 2Health News:My Shiney Hiney® to Participate in ASD Market Week 2015 2
... dyes, researchers have shown that they can identify tumors ... may allow doctors to detect and diagnose cancer earlier ... ScFv peptides that bind cancer cells, the gold particles ... When illuminated with a laser beam, the tumor-bound particles ...
... GLENDALE, Calif., Dec. 23 The California,Nurses ... condolences to the family of Nataline Sarkysian, and ... liver transplant one week,earlier for the 17-year-old, who ... to the procedure following a massive national outcry.,CNA/NNOC ...
... Mylan Inc. (NYSE: MYL ),today announced that due ... 31 to December 31, it is scheduling its next annual ... 25, 2008, as the date of,its 2008 Annual Meeting of ... the Company matters to be brought before the annual,meeting (except ...
... for December 26, 2007 at 5:00 pm ET, ... (Nasdaq: ENSG ), the parent company of the ... living,companies, today timely filed its Form 10-Q and reported ... 2007. The,Company,s third quarter 2007 financial results were consistent ...
... about $555, government analysis shows., , , FRIDAY, Dec. 21 ... cancer for under- or uninsured low-income U.S. women cost ... new government analysis. , The total cost per woman ... is about $555, according to the analysis of the ...
... TAXUS Liberte has more CE Mark-approved indications than any other ... ... Boston Scientific,Corporation (NYSE: BSX ) announced today that its TAXUS(R) ... in patients with diabetes.(1) Boston Scientific submitted,data showing the TAXUS Liberte ...
Cached Medicine News:Health News:Gold nanoparticle probes may allow earlier cancer detection 2Health News:Gold nanoparticle probes may allow earlier cancer detection 3Health News:Nataline Sarkysian Vigil Sunday 2Health News:The Ensign Group, Inc. Reports Third Quarter 2007 Earnings 2Health News:The Ensign Group, Inc. Reports Third Quarter 2007 Earnings 3Health News:The Ensign Group, Inc. Reports Third Quarter 2007 Earnings 4Health News:The Ensign Group, Inc. Reports Third Quarter 2007 Earnings 5Health News:The Ensign Group, Inc. Reports Third Quarter 2007 Earnings 6Health News:The Ensign Group, Inc. Reports Third Quarter 2007 Earnings 7Health News:The Ensign Group, Inc. Reports Third Quarter 2007 Earnings 8Health News:The Ensign Group, Inc. Reports Third Quarter 2007 Earnings 9Health News:Low-Income Women's Cancer Screenings Cost Effective: Report 2Health News:Low-Income Women's Cancer Screenings Cost Effective: Report 3Health News:TAXUS(R) Liberte(TM) Drug-eluting Coronary Stent System Receives CE Mark for Use in Diabetic Patients 2Health News:TAXUS(R) Liberte(TM) Drug-eluting Coronary Stent System Receives CE Mark for Use in Diabetic Patients 3Health News:TAXUS(R) Liberte(TM) Drug-eluting Coronary Stent System Receives CE Mark for Use in Diabetic Patients 4Health News:TAXUS(R) Liberte(TM) Drug-eluting Coronary Stent System Receives CE Mark for Use in Diabetic Patients 5
Conducting disposable tips provide cross-contaminationfree pipetting for sensitive applications such as PCR setup....
300 L, Bulk Recommended for 250 and 300 L pipettes. Can also be used with 20, 25, 50, 100 and 200 L pipette...
... Finntips have been designed to optimize the ... of our tip products is widely recognized ... range has been extended over the years ... standard and special tips including filter tips, ...
... to order tips. Each box contains 10,000 ... available in easy-to-open, re-sealable Bulk Packs of ... sealed with a tamper-proof strip which can ... Gilsons Diamond Tips. Bulk Packs are closed ...
Medicine Products: